Decorte Future Industries (trading as Sonus Health) is a Cambridge‑based deep‑tech company that builds AI that extracts clinical‑grade health signals from ordinary microphone audio to screen and monitor cardiovascular, respiratory, neurological and gastrointestinal conditions using smartphones and simple microphones[2][1].[2]
High‑Level Overview
- Decorte is a product company whose stated mission is to “democratise access to health and wellness screening” by using sound‑based AI (SoNUS / Sonus Engine) to make hospital‑level screening available via standard microphones on consumer devices[2][1].[2]
- The company’s core product is the Sonus Health app and SoNUS AI platform, which applies machine learning and digital signal processing to audio to perform automatic auscultation and extract multiple health markers from a single recording[2][1].[2]
- Primary customers and partners include healthcare providers, insurers and public‑health organizations (and, outside regulated medical use, consumer smartphone users) for remote monitoring, early screening and cost reduction in care delivery[1][2].[1]
- Reported growth momentum includes Techstars London selection (2020), a $1.6M pre‑seed round, UK government innovation grants, partnerships with clinical groups (including US and EU clinics and Apollo Hospitals) and strategic relationships with Microsoft and Google as technology partners[1][3][5].[1]
Origin Story
- Decorte Future Industries was incorporated in the UK on 28 August 2019 and was founded by Dr Roeland P‑J E Decorte following his doctoral work; the company later operated under the consumer brand Sonus Health[4][2].[4]
- The founder’s technical background (Cambridge PhD work on modern methods) and pandemic‑era funding and validation accelerated their focus on sound‑based diagnostics, with UK innovation grants enabling early testing phases and Techstars London providing accelerator support in 2020[3][1].[3]
- Early traction and pivotal moments reported include high reported accuracy in audio‑to‑cardiac signal comparisons (reported 99.6% heart data accuracy in a December 2021 test), the $1.6M pre‑seed close, award recognition (Business Weekly Young Company of the Year 2023) and clinical collaborations that expanded their dataset and capability[3][5][1].[3]
Core Differentiators
- Proprietary foundation model for sound: Decorte claims a proprietary SoNUS / Sonus Engine trained on in‑house datasets to extract multi‑system health markers from a single audio recording, distinguishing it from single‑signal acoustic tools[2][1].[2]
- Microphone‑first approach: Designed to work with standard smartphone or simple microphones rather than specialised stethoscopes or sensors, enabling very broad distribution and low marginal cost per user[2][1].[2]
- Cross‑domain screening: The platform targets cardiovascular, respiratory, neurological and gastrointestinal signals from audio, offering breadth beyond many acoustics‑focused competitors[2][1].[2]
- Strategic partnerships and endorsements: Reported partnerships with Microsoft and Google and board/advisor relationships with experienced executives (including people from Arm, Microsoft and Raspberry Pi) add credibility and potential go‑to‑market and cloud/AI support[1][5].[1]
Role in the Broader Tech Landscape
- Trend alignment: Decorte sits at the intersection of digital health, edge‑enabled AI, and biometric monitoring—trends driven by ubiquitous microphones, lower costs of compute, and demand for remote diagnostics[2][1].[2]
- Timing: Widespread smartphone penetration and increased regulatory and payer interest in remote monitoring create an environment where low‑cost, scalable screening tools can reduce late‑stage disease costs and expand access to underserved populations[2][1].[2]
- Market forces in their favor include healthcare systems’ cost pressures, insurers’ interest in preventive screening, and device OEM/cloud partner appetite to embed differentiated health features into consumer products[1][2].[1]
- Influence on ecosystem: If clinically validated and regulatory‑cleared at scale, such microphone‑based screening could shift early‑detection workflows, lower barriers for population screening, and spur more sensor‑less biometric startups and standards for audio‑based clinical data[2][1].[2]
Quick Take & Future Outlook
- Near term: Expect continued clinical validation, steps toward regulatory pathways for medical use cases, consumer rollouts via the Sonus Health app, and deeper integrations with large tech partners to scale distribution to billions of smartphones as publicly stated targets[2][1][3].[2]
- Key trends to watch: regulatory clearance for diagnostic claims, independent peer‑reviewed clinical trial results, reimbursement models for remote screening, and data‑privacy/AI‑safety practices for audio‑derived health data[1][2].[1]
- Upside / risk: Upside is broad access to low‑cost screening and meaningful healthcare cost savings if accuracy and regulation align; primary risks are clinical/regulatory hurdles, reproducibility in diverse real‑world audio environments, and data‑privacy or adoption barriers within regulated healthcare systems[3][1].[3]
Overall, Decorte Future Industries positions itself as an early mover in foundational audio‑based health AI (Sonus Health), combining proprietary models, clinical partnerships and major tech allies to scale low‑cost screening via ubiquitous microphones—its success will hinge on robust clinical validation, regulatory progress and large‑scale deployment through platform partners[2][1][3].[2]
